Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the pricing of an underwritten public offering of 4,461,209 shares of its common stock at a price to the public of $1.20 per share. All of the shares are being sold by Salarius. The gross proceeds to Salarius from the offering, before deducting the underwriting discounts and commissions and other
July 30, 2020
· 3 min read